{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:03Z","timestamp":1790746803464,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>There is currently no consensus on the optimal treatment of early myelofibrosis (MF). Ropeginterferon alfa-2b (ropeg) is a next-generation monopegylated interferon alfa-2b developed specifically to treat myeloproliferative neoplasms. We conducted a phase 2 study in patients with prefibrotic primary MF (pre-PMF) and Dynamic International Prognostic Scoring System low-\/intermediate-1\u2013risk fibrotic PMF or secondary MF (SMF) who required cytoreduction. Ongoing treatment with hydroxyurea was substituted with ropeg (week 0, 250 \u03bcg; week 2, 350 \u03bcg; week 4 onward, 500 \u03bcg every 2 weeks). The primary end points were safety and clinicohematologic complete response (CHCR). Seventy-one patients (40 men and 31 women) with a median age of 60 years (range, 31-86) were enrolled and followed up for a median of 119 weeks (range, 10-131). At weeks 24, 48, and 104, CHCR was achieved in 63.8% (pre-PMF, 74%; fibrotic PMF, 20%; fibrotic SMF, 42.9%), 63.5% (pre-PMF, 69.6%; fibrotic PMF, 25%; SMF, 53.9%), and 70% of patients (pre-PMF, 78.4%; fibrotic PMF, 33.3%; SMF, 50%), respectively. Thrombo-hemorrhagic events were not observed after stopping hydroxyurea. At weeks 24, 48, and 104, reduction in JAK2V617F variant allele frequency (VAF) was observed in 53.1%, 70%, and 67.6% of patients, and reduction in CALR mutant VAF was observed in 52.6%, 42.9%, and 40% of patients, respectively. In 50 evaluable cases at week 104, 13 patients (26%) had reduced bone marrow reticulin fibrosis. There were 3 treatment discontinuations (4.2%) due to adverse events. In conclusion, ropeg was safe and induced CHCR associated with significant molecular responses in patients with early MF. This trial was registered at www.clinicaltrials.gov as NCT04988815.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019612","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:53:06Z","timestamp":1774374786000},"page":"3920-3930","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-8918","authenticated-orcid":false,"given":"Lester","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1247","authenticated-orcid":false,"given":"Rita","family":"Yim","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-0435","authenticated-orcid":false,"given":"Paul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-8852","authenticated-orcid":false,"given":"Vivian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2450-2008","authenticated-orcid":false,"given":"Lynn","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yan","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4505-4166","authenticated-orcid":false,"given":"Carmen Y. Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-7950","authenticated-orcid":false,"given":"Tony K. Y.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret M. K.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"7","key":"2026060911320042900_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"2026060911320042900_bib2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023022415","article-title":"How I individualize selection of JAK inhibitors for patients with myelofibrosis","volume":"145","author":"Masarova","year":"2025","journal-title":"Blood J"},{"issue":"10","key":"2026060911320042900_bib3","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review","volume":"96","author":"Kc","year":"2017","journal-title":"Ann Hematol"},{"issue":"9","key":"2026060911320042900_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2026060911320042900_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"2026060911320042900_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-020-00368-1","article-title":"A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis","volume":"10","author":"Carobbio","year":"2020","journal-title":"Blood Cancer J"},{"issue":"24","key":"2026060911320042900_bib7","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026060911320042900_bib8","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026060911320042900_bib9","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-024-05665-4","article-title":"ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options","volume":"103","author":"Kiladjian","year":"2024","journal-title":"Ann Hematol"},{"issue":"19","key":"2026060911320042900_bib10","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2026060911320042900_bib11","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026060911320042900_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/hematology.2024000577","article-title":"Pegylated interferon: the who, why, and how","volume":"2024","author":"Kiladjian","year":"2024","journal-title":"Hematology"},{"issue":"24","key":"2026060911320042900_bib13","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2026060911320042900_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"issue":"14","key":"2026060911320042900_bib15","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2026060911320042900_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","article-title":"Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","volume":"28","author":"Pizzi","year":"2015","journal-title":"Mod Pathol"},{"issue":"5","key":"2026060911320042900_bib17","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/bcp.15176","article-title":"Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial","volume":"88","author":"Huang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2026060911320042900_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","article-title":"Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration","volume":"41","author":"Miyachi","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"27","key":"2026060911320042900_bib19","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2217\/fon-2022-0596","article-title":"SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"1-2","key":"2026060911320042900_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/jh1245","article-title":"Effective management of polycythemia vera with ropeginterferon alfa-2b treatment","volume":"13","author":"Suo","year":"2024","journal-title":"J Hematol"},{"issue":"5","key":"2026060911320042900_bib21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026060911320042900_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s44276-024-00076-4","article-title":"Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia","volume":"2","author":"Kirito","year":"2024","journal-title":"BJC Rep"},{"issue":"10","key":"2026060911320042900_bib23","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/cam4.2865","article-title":"Clofarabine, cytarabine, and mitoxantrone in refractory\/relapsed acute myeloid leukemia: high response rates and effective bridge to allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Gill","year":"2020","journal-title":"Cancer Med"},{"issue":"23","key":"2026060911320042900_bib24","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2026060911320042900_bib25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026060911320042900_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"2026060911320042900_bib27","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"2026060911320042900_bib28","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026060911320042900_bib29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-\u03b1-2b therapy in BCR-ABL\u2013negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2026060911320042900_bib30","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon \u03b1-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"2026060911320042900_bib31","doi-asserted-by":"crossref","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid"},{"issue":"18","key":"2026060911320042900_bib32","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1200\/JCO.2011.35.6238","article-title":"Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"29","author":"Hasselbalch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911320042900_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/17474086.2015.1045409","article-title":"Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?","volume":"8","author":"Hasselbalch","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"2026060911320042900_bib34","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/cas.15376","article-title":"Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia","volume":"113","author":"Sakatoku","year":"2022","journal-title":"Cancer Sci"},{"issue":"6","key":"2026060911320042900_bib35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp Hematol"},{"issue":"12","key":"2026060911320042900_bib36","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood.V84.12.4142.bloodjournal84124142","article-title":"Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist","volume":"84","author":"Aman","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2026060911320042900_bib37","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026060911320042900_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2026060911320042900_bib39","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"2026060911320042900_bib40","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1007\/s00277-024-05912-8","article-title":"A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early\/lower-risk primary myelofibrosis","volume":"103","author":"Abu-Zeinah","year":"2024","journal-title":"Ann Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3920\/2523638\/blooda_adv-2026-019612-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3920\/2523638\/blooda_adv-2026-019612-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:11Z","timestamp":1781019131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3920\/567386\/Ropeginterferon-alfa-2b-for-prefibrotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019612","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,28]]}}}